CTLA4 and cancer: Since the recent encouraging clinical responses observed in patients who had been treated with mabs against the immune checkpoint proteins cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death (PD-1), the interest of the scientific community shifted in using such immune checkpoint blockade for treating cancer patients [63].